Kidney Week

Abstract: SA-PO968

Genetic Evaluation of Living Kidney Donor Candidates: Results from the LDGen Registry

Session Information

• Transplantation: Clinical - 3
  October 26, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

• 2102 Transplantation: Clinical

Authors

• Caliskan, Yasar, Saint Louis University, St Louis, Missouri, United States

Yasar Caliskan, MD

• Oto, Ozgur Akin, Istanbul Universitesi, Fatih, Istanbul, Turkey

Ozgur Akin Oto, MD

• Alhamad, Tarek, Washington University in St Louis, St Louis, Missouri, United States

Tarek Alhamad, MD, MBA, MPH, FASN

• Yazici, Halil, Istanbul Yeni Yuzyil Universitesi, Istanbul, İstanbul, Turkey

Halil Yazici, MD

• Yildiz, Abdulmecit, Bursa Uludag Universitesi, Nilufer, Bursa, Turkey

Abdulmecit Yildiz, MD

• Velioglu, Arzu, Marmara Universitesi, Istanbul, Istanbul, Turkey

Arzu Velioglu, MD

• Garg, Neetika, University of Wisconsin-Madison, Madison, Wisconsin, United States

Neetika Garg, MD

• Soliman, Karim, Medical University of South Carolina, Charleston, South Carolina, United States

Karim Soliman, MBChB, MSc, PhD, FASN

• Jittirat, Arksarapuk, Case Western Reserve University, Cleveland, Ohio, United States

Arksarapuk Jittirat, MD

• Viklicky, Ondrej, Institut Klinicke a Experimentalni Mediciny, Praha, Czechia

Ondrej Viklicky, MD, PhD

• Ural, Zeynep, Gazi Universitesi, Ankara, Ankara, Turkey

Zeynep Ural, MD

• Mejia, Christina Irene, Johns Hopkins University, Baltimore, Maryland, United States

Christina Irene Mejia, MD

• Daloul, Reem, Allegheny Health Network, Pittsburgh, Pennsylvania, United States

Reem Daloul, MD

• Radunovic, Danilo, Klinicki Centar Crne Gore, Podgorica, Montenegro

Danilo Radunovic

• Lee, Brian, Dell Seton Medical Center at The University of Texas, Austin, Texas, United States

Brian Lee, MD, MBChB

• Thomas, Christie P., University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Christie P. Thomas, MBBS, FASN

• Trujillo Cuellar, Hernando, Hospital Universitario 12 de Octubre, Madrid, Comunidad de Madrid, Spain

Hernando Trujillo Cuellar, MD

• Mannon, Roslyn B., University of Nebraska System, Lincoln, Nebraska, United States

Roslyn B. Mannon, MD, FASN

• Lentine, Krista L., Saint Louis University, St Louis, Missouri, United States

Krista L. Lentine, MD, PhD, FASN

Group or Team Name

• LDGen Consortium.

Background

We describe our preliminary experience with the launch of a novel international Registry – “LDGen” – as a repository to study current and evolving practices in genetic testing as part of living donor (LD) candidate evaluation.

Methods

A cross-sectional, electronic REDCap registry was developed to collect information on LD candidates and their genetic test results. LD candidates who either 1) underwent genetic testing, and/or 2) had a family history of genetic kidney disease, or 3) are looking to donate to a related recipient with kidney disease of unknown etiology were registered. Data reported here were collected between June, 2023 and May, 2024.

Results

Data on 1004 LD evaluations were obtained representing 12 U.S. and 9 international centers. 39% (n=305) of intended recipients had possible genetic kidney disease. Genetic testing was performed in 17% (n=168) of LD evaluations. Testing in recipient candidate was performed before the LD candidate in 73% (n=122) of cases while it was performed only in the donor candidate in 27% (n=46) of evaluations (Fig. 1A). 125 LD candidates underwent genetic testing and 81% of these donors received formal pre-test genetic counseling. Single gene/limited gene panel (42%) and broad kidney disease gene panel (29%) were the most common methods. 33% (n=41) of the LD candidates who underwent genetic testing during evaluation were not accepted, of which 51% (n=21) of declinations were due to the genetic testing result [Pathogenic/Likely pathogenic variant (n=9), renal risk variants (n=2), VUS (n=10)] (Fig.1B).

Conclusion

Our initial experience supports the feasibility of international collaboration in creating a registry of genetic kidney disease testing practices among LD candidates. With more data, the findings of the LDGen registry will provide value information on global LD evaluation practice patterns.